CareDx Shares Surge 22% Following Strong Q3 Growth and Raised Guidance
CareDx (CDNA) shares jumped over 22% following the release of robust third-quarter financial results. The medical diagnostics provider reported a 39% year-over-year revenue increase to $139 million, fueled largely by a 65% surge in testing services revenue. This growth was supported by a 51% rise in testing volumes and the strategic acquisition of cancer blood-test maker Naveris. Driven by strong performance in precision medicine diagnostics and pharmacy services, the company doubled its EBITDA to $30 million for the quarter. Consequently, management raised its full-year 2026 revenue guidance to approximately $525 million and increased its adjusted EBITDA target to a range of $90 million to $100 million.
Tickers: $CDNA
Topics: EBITDA guidance upgrade medical diagnostics revenue growth testing volumes